Basiliximab induction in patients receiving tacrolimus-based immunosuppressive regimens.

about

Near-term anti-CD25 monoclonal antibody administration protects murine liver from ischemia-reperfusion injury due to reduced numbers of CD4+ T cells Basiliximab: efficacy and safety evaluation in kidney transplantation.

P2860

Q34134224-798BA60F-6531-41BD-9FC1-D68A73B40361 Q38165224-B17F21CD-8958-4F81-91F9-F9AE7E4174A5

P2860

Basiliximab induction in patients receiving tacrolimus-based immunosuppressive regimens.

Item

http://www.wikidata.org/entity/Q46553783

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Basiliximab induction in patients receiving tacrolimus-based immunosuppressive regimens.

@en

Basiliximab induction in patients receiving tacrolimus-based immunosuppressive regimens.

@nl

type

Item

label

Basiliximab induction in patients receiving tacrolimus-based immunosuppressive regimens.

@en

Basiliximab induction in patients receiving tacrolimus-based immunosuppressive regimens.

@nl

prefLabel

Basiliximab induction in patients receiving tacrolimus-based immunosuppressive regimens.

@en

Basiliximab induction in patients receiving tacrolimus-based immunosuppressive regimens.

@nl

P1476

Basiliximab induction in patients receiving tacrolimus-based immunosuppressive regimens

@en

P2093

Cláudia Rosso Felipe

http://www.w3.org/2001/XMLSchema#string

Hélio Tedesco-Silva

http://www.w3.org/2001/XMLSchema#string

Marcello Fabiano de Franco

http://www.w3.org/2001/XMLSchema#string

Tainá Veras de Sandes-Freitas

http://www.w3.org/2001/XMLSchema#string

P2860

Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids.

Early outcomes of thymoglobulin and basiliximab induction in kidney transplantation: application of statistical approaches to reduce bias in observational comparisons.

Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: a review.

Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.

Use of basiliximab induction in low-immunological risk renal transplant recipients receiving tacrolimus-based immunosuppression.

Low rate of acute rejection and cytomegalovirus infection in kidney transplant recipients with basiliximab.

Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial.

Induction immunosuppressive therapy in renal transplantation: does basiliximab make the difference?

Anti-CD25 monoclonal antibody sequential immunosuppressive induction therapy in renal transplants with high risk of delayed graft function.

Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era.

P304

537-546

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11255-012-0298-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

José O Medina Pestana

P577

2012-10-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23054318

http://www.w3.org/2001/XMLSchema#string

Basiliximab induction in patients receiving tacrolimus-based immunosuppressive regimens.

about

P2860

P2860

Basiliximab induction in patients receiving tacrolimus-based immunosuppressive regimens.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698